Is CBD legal? An analysis of CBD legislation in Switzerland and elsewhere

With the growing enthusiasm for CBD, it is becoming essential to be informed about the applicable laws.

Recognized for its potential therapeutic benefits without the psychoactive effects of THC, the main active component of cannabis, CBD's regulation varies significantly from one country to another. This diversity of legal frameworks can be confusing for consumers and businesses.

This article offers a thorough examination of the laws regulating CBD in Switzerland, our primary focus, while also providing a brief comparison with regulations in other key regions. By detailing the intricacies of these legal frameworks, we aim to clarify the rules for the legal purchase and consumption of CBD , thereby helping our audience navigate this complex landscape.

The legal status of CBD in Switzerland

In Switzerland, cannabis containing less than 1% THC is not subject to the Narcotics Act. This includes CBD products, which are increasingly being marketed commercially. CBD is particularly touted for its potential anti-inflammatory, anticonvulsant, antiemetic, and anxiolytic effects, although medical research remains insufficient to conclusively confirm these therapeutic effects. CBD products must, however, comply with the Therapeutic Products Act, the Foodstuffs Act, or the Product Safety Act, depending on their product category ( Admin.ch ) ( BLV.admin ) .

Regulatory framework for cannabis for non-medical use

In May 2021, an amendment to the Federal Act on Narcotics and Psychotropic Substances was introduced, allowing pilot trials for the distribution of cannabis for non-medical purposes. These trials aim to assess the impacts of controlled access to cannabis and will provide a scientific basis for future regulations. This framework will allow for the study of the effects on the physical and mental health of users, as well as the socio-economic implications, while eliminating the risks associated with the black market ( Admin.ch ) .

Situation in the European Union

Within the EU, the situation varies considerably between member states. CBD is often regulated based on the THC content of products. Products containing CBD that are classified as novel foods require authorization before being placed on the market, in accordance with the European Commission's catalogue of novel foods.

The regulatory situation for CBD in the European Union is complex and subject to differing interpretations among the various Member States. In January 2019, cannabidiol (CBD) was added to the Catalogue of Novel Foods, meaning that any company wishing to market CBD-based products in the EU must obtain prior authorization. However, the temporary suspension of the authorization process led to varied reactions: some Member States began withdrawing CBD-containing products from the market, while others continued selling them or did not strictly enforce the rules.

The European Food Safety Authority (EFSA) is currently evaluating 19 applications for authorization of CBD products. The evaluation of these products has revealed data gaps and uncertainties regarding the safety of CBD as a novel food. Before reaching a conclusion on the safety of CBD, EFSA indicates that these gaps need to be addressed in order to establish accurate and reliable recommendations.

In light of this situation, it is crucial for both producers and consumers of CBD products to closely monitor regulatory developments within the EU. The European Commission has been asked to take concrete steps to prevent divergent interpretations of EU law in the single market and to ensure that producers and consumers benefit from equal and predictable conditions. Meanwhile, regulatory diversity among Member States remains a major challenge for the CBD industry in Europe.

For detailed information, you can consult the EFSA's FAQ on CBD and the parliamentary questions to the European Commission regarding the availability and conditions of sale of CBD products on the EU single market. These documents are available on the respective websites of EFSA and the European Parliament .

In Europe, the legality of CBD varies from country to country, with laws ranging from full authorization to total prohibition.

Some countries allow the purchase of CBD products containing less than 0.2% THC, while others require a medical prescription. In Austria, for example, CBD is no longer sold as a medicine, but products with less than 0.3% THC are legal. In France, CBD is legal if the products do not contain THC. Each member state applies these guidelines with nuances specific to its national context. For a precise overview, details specific to each EU member state are available on the Legal Reader website .

In conclusion, the regulation of CBD in Switzerland offers a unique and progressive framework that could serve as a model for other countries.

With its specific regulations tailored to cosmetics, utility products, and even tobacco substitutes, Switzerland is positioning itself at the forefront of the legal cannabis industry. Pilot trials for the sale of cannabis for recreational purposes could further positively influence future legislation, promising an interesting evolution in laws concerning CBD and cannabis in general. For entrepreneurs and consumers, understanding this regulatory dynamic is crucial for navigating effectively in a constantly evolving market. Thus, while Europe presents a diverse picture of CBD legality, developments in Switzerland could eventually inspire a more harmonized approach across the continent.